natgillin/translations-raw huggingface dataset:
a compound as an active ingredient, wherein the compound has a formula: wherein R is substituted adamantyl and n is an integer from 0 to 3; or a pharmaceutically acceptable salt thereof; and 
spoj kao aktivni sastojak, pri čemu spoj je (S)-1-[(3-hidroksi-1-adamantil)amino]acetil-2-cijano-pirolidin (vildagliptin) ili odgovarajuću količinu bilo koje od njegovih soli; te
A use of a transdermal delivery device according to any one of claims 1 to 20 in the preparation of a medicament to provide analgesia to a patient in need thereof. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 1, naznačen time da je količina antagonista u pojedinoj mikrosferi od 5 % do 70 % po težini.
The compound for use according to claim 11 wherein the cancer is identified as p53wildtype (p53WT). 
Lijek za uporabu prema zahtjevu 14 ili 15, pri čemu se lijek koristi u kombinaciji s radioterapijom.
The apparatus of claim 7, wherein the L2 signaling data includes a Network Information Table, NIT, having an identifier of a physical layer pipe (PLP_id) and an identifier of a C2 system (C2_system_id) corresponding to the transport stream, TS; and wherein a C2 delivery system descriptor includes the identifier of the PLP and the identifier of the C2 system in a TS loop of the NIT maps transport streams to PLPs in data slices of the C2 systems. 
modulaciju okvira signala pomoću ortogonalne modulacijske tehnike u frekvencijskoj domeni (OFDM); i odašiljanje moduliranog okvira signala, gdje deskriptor C2 dostavnog sustava, uključujući identifikator PLP-a i identifikator C2 sustava u TS petlji NIT mapa, prenosi tokove do PLP-ova u podatkovnim komadima C2 sustava. Postupak prema zahtjevu 7, gdje NIT obuhvaća identifikator prijenosnog toka i identifikator mreže.
In particular ammonia caramel (class III) constitutes an excellent starting material for the production of a light stabilising composition according to the invention. 
Naročito amonij karamela (klasa III) predstavlja odličan početni materijal za proizvodnju pripravka za stabiliziranje na svjetlo prema izumu.
The number of falls. 
Broj objave europskog patenta:
GLP-1 (7 - 37) of SEQ ID No. 1 or a functional sequence exerting the biological effects of GLP-1 as incretin hormone, its anti-apoptotic action or its neurotrophic properties and having at least 80% sequence identity with GLP-1 (7 - 37), 
(i) GLP-1 (7-37) sa SEQ ID NO: 1 ili funkcionalnu sekvencu koja ima biološko djelovanje GLP-L kao inkretinskog hormona, njegovo antiapoptotičko djelovanje ili njegova neurotrofna svojstva i koja ima najmanje 80% identiteta sekvence sa GLP-1 (7-37), ili
shows an extraction capsule known from EP-A-512470, 
prikazuje čahuru za istakanje koja je poznata iz EP-A-512470,
liquid tumour cancer; or hematological cancer; or colon cancer, gastric cancer, breast cancer, lung cancer, acute myeloid leukemia, thyroid cancer, ocular cancer, prostate cancer, ocular melanoma cancer, ovarian cancer, renal cancer, skin cancer, or squamous cell carcinoma. 
Tak čvrstog tumora; ili rak tekućeg tumora; ili hematološki rak; ili rak debelog crijeva, gastrički rak, rak dojke, rak pluća, akutna mijeloidna leukemija, tiroidni rak, očni rak, rak prostate, rak očnog melanoma, rak jajnika, rak bubrega, rak kože ili karcinom rožnatih stanica.
The device of claim 1, wherein the circulating tumor cells are derived from a solid tumor. 
Postupak prema bilo kom od patentnih zahtjeva 12 do 14, pri čemu veće čestice jesu cirkulirajuće stanice tumora
A package comprising: a) at least one glove of any one of claims 1-14 and instructions for its use. 
Pakiranje, naznačeno time što sadrži: a) najmanje jednu rukavicu u skladu s bilo kojim od patentnih zahtjeva 1-14 upute za njezinu upotrebu.
A method of pushing a vehicle to slide upward on a bottom surface of the vehicle along a sliding surface of a channel of a waterslide comprising impacting water impact surfaces spaced along opposite sides of the vehicle body with a plurality of water spray sources positioned to provide a flow of water over the sliding surface and adapted to affect the sliding motion of the vehicle. 
Postupak za potiskivanje vozila da klizi prema gore na donjoj površini vozila duž klizne površine kanala vodenog tobogana naznačen time što obuhvaća udaranje vode u udarne površine za vodu koje su razmaknute uzduž suprotnih strana tijela vozila s mnoštvom izvora za raspršivanje vode smještenim da osiguravaju strujanje vode preko klizne površine 1 prilagođenim da utječu na klizno kretanje vozila.
The international patent application No. 
Broj europske prijave patenta:
A packaging system as claimed in any preceding claim, wherein said packaging apparatus includes a package material dispensing apparatus operable to dispense said packaging material, preferably in increments in which a pre-determined length of packaging material is dispensed. 
Sustav za pakiranje sukladno bilo kojem od ranijih zahtjeva, pri čemu navedeni uređaj za pakiranje (40,140) uključuje uređaj za materijal za pakiranje (174) koji je u mogućnosti izdati navedeni materijal za pakiranje (170), po mogućnosti u pomacima u kojima se izdaje prethodno određena duljina materijala za pakiranje.
The composition of claim 13, wherein the non-hydrolyzing conditions comprise a temperature of from 20-30°C and a non-aqueous reaction medium. 
Sastav u skladu sa zahtjevom 13, naznačen time, što nehidrolizirani uvjeti obuhvaćaju temperaturu od 20 do 30 *€ i nevodenu reakciju medija.
Capsule formulations may be of the hard gelatin or soft gelatin variety and can contain the active component in solid, semi-solid, or liquid form. 
Formulacije kapsula mogu biti u čvrstim ili mekanim oblicima i mogu sadržavati aktivni sastojak u krutom, polu-krutom ili tekućem obliku.
A composition according to claim 28, which, in addition to comprising the compound of Formula (I), comprises a safener. 
Sastav, prema zahtjevu 30, naznačen time, da dodatno uz sadržaj spoja formule (I) obuhvaća i neškodljivo zaštitno sredstvo.
Start the stirrer on slow speed and add 2.2 kg of Toffee Flavour QL17192. 
Uključiti mješalicu na sporu brzinu 1 dodati 2.2 kg arome karamele QL17192.
A pharmaceutical composition comprising a compound according to any one of claims 1 - 8 and a pharmaceutical acceptable carrier and/or adjuvant for use in the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders. 
Farmaceutski pripravak, naznačen time, da se sastoji od spoja u skladu s bilo kojim od patentnih zahtjeva od 1 do 8 1 farmaceutski prihvatljivog nosača i/ili pomoćne tvari, pri čemu se on upotrebljava u liječenju depresije, poremećaja anksioznosti, bipolarnog poremećaja, hiperaktivnog poremećaja manjka pozornosti (ADHD), poremećaja uzrokovanih stresom, psihotičnih poremećaja, shizofrenije, neuroloških bolesti, Parkinsonove bolesti, neurodegenerativnih poremećaja, Alzheimerove bolesti, epilepsije, migrene, hipertenzije, zlouporabe droga, metaboličkih poremećaja, poremećaja hranjenja, dijabetesa, dijabetičkih komplikacija, pretilosti, dislipidemije, poremećaja potrošnje energije i asimilacije, poremećaja i oštećenja homeostaze tjelesne temperature, poremećaja spavanja 1 cirkadijalnog ritma te kardiovaskularnih poremećaja.
The method of claim 3 wherein the pH is about to about 4 pH units below the pI of the polypeptide. The method of claim 3 wherein the pH is about 1 to about 3 pH units below the pI of the polypeptide. 
Postupak prema patentnom zahtjevu 1, naznačen time, da pH u njemu iznosi: oko 1 do oko 4 pH-jedinice ispod pI-vrijednosti monoklonskog protutijela; oko 1 do oko 3 pH-jedinice ispod pI-vrijednosti monoklonskog protutijela;
[SEQ ID NO: 30] CARILRGGSGMDL. In a particularly preferred embodiment of the invention, the antibody, fragment, variant, fusion or derivative comprises a variable heavy chain (VH) comprising the CDRs of SEQ ID NO:28 and SEQ ID NO:29 and SEQ ID NO:30. 
Protutijelo ili fragment za vezanje antigena prema zahtjevu 1, naznačeno time da protutijelo ili fragment za vezanje antigena ima veću snagu za aktivaciju dendritske stanice nego B44 protutijelo koje sadrži sekvencu amino kiselina varijabilnog lakog lanca SEQ ID NO:58 1 sekvencu amino kiselina varijabilnog teškog lanca SEQ ID NO:60.
The thickness of intimal layer of the aorta is shown in table 10. 
Debljina unutarnjeg sloja aorte prikazana je u tablici 10.
PM01183, or a pharmaceutically acceptable salt thereof, for use in increasing the therapeutic efficacy of a topoisomerase I and/or II inhibitor in the treatment of cancer, which comprises administering to a patient in need thereof a therapeutically effective amount of PM01183, or a pharmaceutically acceptable salt thereof, in synergistic combination with said topoisomerase I and/or II inhibitor, wherein the topoisomerase I and/or II inhibitor is selected from topotecan, SN-38, irinotecan, camptothecin, rubitecan, etoposide and teniposide. 
PM01183, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u povećavanju terapijske djelotvornosti antimetabolita u liječenju raka, naznačen time što se upotreba sastoji u primjeni na pacijentu kojem je to potrebno terapijski djelotvorna količina PM01183, ili njegove farmaceutski prihvatljive soli, u sinergističkoj kombinaciji s navedenim antimetabolitom, gdje se antimetabolit bira između 5-fluoruracila, gemcitabina, citarabina, kapecitabina, decitabina, floksuridina, aminopterina, metotreksata, pemetrekseda i raltitrekseda.
a bispecific antibody (Q31-z7/J326-z107/L2-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 2, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 6, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 8; 
bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 2, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 6, a treći polipeptid i četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 8;
The pharmaceutical composition of claim 10, wherein the solvent is acetonitrile. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što je otapalo acetonitril.
Preferably the third ring member is fixed in use to prevent rotation of the third ring member. Preferably, the third ring member also comprises a limiting mechanism to limit free rotation of the second ring member relative to the third ring member about the common axis. 
Brojač kao što je navedeno u zahtjevu 15, naznačeno time da navedeni treći prstenasti element (1502) sadrži mehanizam ograničenja (1506) za ograničavanje slobodne rotacije navedenog drugog prstenastog elementa (202, 1510) u odnosu na navedeni treći prstenasti element oko navedene zajedničke osi.
at least 7% of the cells in the population express detectable levels of CD126; 
(x) najmanje 7 % stanica u populaciji na svojoj površini izražava uočljive razine CD126;
The polypeptide multimer of any one of claims 37 to 39, wherein the first polypeptide having an antigen-binding activity and the second polypeptide having an antigen-binding activity or no antigen-binding activity comprise an amino acid sequence of an antibody Fc domain or an amino acid sequence of anantibody heavy-chain constant region; wherein the amino acid residue of position 435 (EU numbering) in the amino acid sequence of the antibody Fc domain or antibody heavy-chain constant region is histidine or arginine in either one of the first polypeptide having an antigen-binding activity and the second polypeptide having an antigen-binding activity or no antigen-binding activity; and wherein the amino acid residue of position 435 (EU numbering) in the amino acid sequence of the antibody Fc domain or antibody heavy-chain constant region in either one of said polypeptides is different from that in the other polypeptide. 
pri čemu Fc domena antitijela ili konstantna regija teškog lanca antitijela je izvedena iz humanog IgG; pri čemu aminokiselinski ostatak na položaju 435, u skladu sa EU numeriranjem, u aminokiselinskoj sekvenci Fc domene ili konstantne regije teškog lanca je histidin ili arginin u prvom polipeptidu i arginin ili histidin redom u drugom polipeptidu; pri čemu aminokiselinska kombinacija na položajima 356 i 439 u aminokiselinskoj sekvenci Fc regije ili konstantne regije teškog lanca prvog polipeptida je modificirana u aminokiseline sa istim električnim nabojem; i pri čemu aminokiselinska kombinacija na položajima 356 i 439 u aminokiselinskoj sekvenci Fc regije ili konstantne regije teškog lanca drugog polipeptida je modificirana u aminokiseline sa električnim nabojem suprotnim od onog za položaje 356 i 439 prvog polipeptida.
The process according to claim 5 or 6 wherein said decreasing ethanol concentration in step a. ranges from about 96% ethanol to about 0% ethanol. 
Postupak u skladu s patentnim zahtjevom 5 ili 6, naznačen time, da je navedena smanjena koncentracija etanola u fazi a. u rasponu od oko 96 % etanola do oko 0 % etanola.
The process of claim 1 wherein said copper carboxylate is selected from the group consisting of copper acetate, copper naphthenate, copper quinolinolate, copper stearate, copper benzoate, copper ethylhexanoate, copper rosinate, and combinations thereof. 
. Sastav prema zahtjevu 1, naznačen time da je bakar-karboksilat odabran iz skupine, koja se sastoji iz bakar-acetata, bakar-naftenata, bakar-kinolinolata, bakar-stearata, bakar-benzoata, bakar-etilheksanoata, bakar-rezinata i njihovih kombinacija.
The weight ratios specified below are based on the compound (b) expressed as (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide and the corticosteroids budesonide and beclomethasone dipropionate which are particularly preferred according to the invention. 
Dolje navedeni težinski omjeri temelje se na spoju (b) koji spoj je (3R)-1-fenetil-3-(9H-ksanten-9-karboniloksi)-1- azoniabiciklo[2.2.2|oktan bromid i slobodnim bazama B2 agonista salmctcrola i formotcrola koji su osobito poželjni sukladno predmetnom izumu.
In some embodiments, the temperature of the tobacco material may reach between about 55° C. and about 90° C., between about 55° C. and about 80° C., or between 60° C. and about 70° C. The tobacco may be secured within the moisture-retaining material for a sufficiently long period of time for the tobacco to develop the desirable organoleptic properties, and for a sufficiently short period of time to not cause unwanted delay in the tobacco supply chain. The tobacco material is secured within the moisture-retaining material for a period of time and at an ambient processing temperature and ambient processing humidity suitable to give rise to an increase in the temperature of the tobacco to or above a threshold temperature, wherein the moisture content of the tobacco is between about 10% and 23%. 
Postupak u skladu s bilo patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što duhanski materijal ima gustoću pakiranja na osnovi težine suhe tvari između 200 kg/m? i 500 kg/m", i/ili što duhanski materijal ima sadržaj vlage između 10 % i 18 % prije i tijekom obrade, i/ili što je duhanski materijal osiguran unutar materijala koji zadržava vlagu u trajanju između 5 i 65 dana, i/ili što je duhanski materijal izložen okolišnoj temperaturi obrade iznad 55 "€. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je duhanski materijal izložen okolišnoj temperaturi obrade od najmanje 45 "C ili iznad 55 "C u trajanju od najmanje 10 dana, i/ili između 10 1 40 dana, i/ili što temperatura duhanskog materijala dostiže obradu na temperaturi okoliša unutar 4 do 10 dana.
A smoking article characterized in that it comprises a wrapper obtainable by the method described in any one of claims 1 to 15. 
Proizvod koji se puši, naznačen time što sadrži papirni omotač koji se može dobiti postupkom opisanim u jednom od Zahtjeva 4 ili 17.
mixing the dietary fibre preparation of plant origin with the at least one cyclodextrin, adding water, 
miješanje pripravka dijetalnih vlakana biljnog porijekla s barem jednim ciklodekstrinom, b. - dodavanje vode,
The pharmaceutical composition according to claim 1 or 2, wherein at least one peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, pri čemu navedeni peptid uključuje nepeptidne veze.
the second fragment is a toxin B repeating domain fragment and comprises at least 100 amino acids; 
(ii) drugi fragment je fragment ponavljajuće domene toksina B iz bakterije C. difficile;
The composition for use of claim 3, wherein the anti-CD47 antibody is a fully human, humanized or chimeric antibody. 
Sastav za upotrebu prema zahtjevu 4, gdje je anti-CD47 antitijelo potpuno humano, humanizirano ili kimerno antitijelo.
Comparison of Serum Cholesterol Levels in Rats Treated with Rapamycin and 42-O-(D-Fructosylcarbonyl)rapamycin 42-O-(D-fructosylcarbonyl)rapamycin and rapamycin were tested head-to-head in Sprague-Dawley rats for changes in cholesterol level. 
Usporedba serumskih razina kolesterola u štakora tretiranih rapamicinom i 42-0-(D-fruktozilkarbonil)rapamicinom 42-0-(D-fruktozilkarbonil)rapamicin i rapamicin testirani su u Sprague-Dawley štakora radi praćenja promjena u razinama kolesterola.
the derivative of formula (X) is subjected to the action of triphosgene and the isocyanate corresponding to the compound of formula (X) is formed, which is condensed with an amine of formula RaNH2, Ra being as defined in Claim 1, in order to obtain the urea of formula (XI): 
derivat s formulom (X) se podvrgava djelovanju trifosgena i nastaje izocijanat koji odgovara spoju s formulom (X), koji je kondenziran s aminom s formulom RaNH2, Ra je kako je definirano u zahtjevu 1, kako bi se dobilo ureu s formulom (XI): [image]
The boom mountable robotic arm of claim 1 wherein said beam includes a main beam member and an extension member at least one end of said main beam member, said extension member extending so as to elongate said beam, and wherein said at least one electrically insulated support post is mounted on a distal end of said extension member, distal from said main beam member. 
Robotska ruka prema zahtjevu 1, naznačena time, da navedena nosiva greda obuhvaća glavni gredni element (28) i nosivi nastavak (36, 38) na barem jednom kraju od navedenog glavnog grednog elementa, pri čemu se taj nosivi nastavak proteže tako, da produžuje navedenu nosivu gredu, te time, da se najmanje jedan HR P20171730 T1 od spomenuta najmanje dva električno izolirana potporna stupa, montira na distalnom kraju od navedenog nosivog nastavka, distalno od glavnog grednog elementa.
The method of claim 2, wherein the request for interruption represents a plurality of message signaled interruptions, and the interruption to the operating system is part of an input/output adapter event notification for the operating system. 
Postupak sukladno Zahtjevu 2, pri čemu zahtjev za prekidom predstavlja više porukom signaliziranih prekida, i prekid operativnog sustava je dio obavijesti ulaznog / izlaznog adaptera za operativni sustav.
subjecting the biological samples of (i) to real-time quantitative PCR (qPCR) comprising: 
(1i) podvrgavanja bioloških uzoraka iz koraka (1) kvantitativnom PCR-u u stvarnom vremenu (qPCR), koji se sastoji u:
Lozenges prepared in specific embodiments of the invention, described in more detail in the examples, demonstrated long-term active agent stability. 
Tablete pripremljene u posebnim varijantama prema izumu, detaljnije opisane u primjerima, pokazale su dugotrajnu stabilnost aktivnog sredstva.
L -Y-glutamyl-3-[(4-biphenylylmethyl)sulfonyl]- L -alanyl- D -phenylglycine, 11A, as the hydrochloride salt, was prepared from in three steps from 330 mg N-a-(benzyloxycarbonyl)- L -Y-glutamyl- L -cysteinyl- D -phenylglycine by dissolving the amine-protected peptide in acetonitrile/water, adding an approximate 10-fold excess of sodium bicarbonate, and adding a slight excess of 4-(bromomethyl)biphenyl, then maintaining the reaction under nitrogen until completion. 
L-v-glutamil-3-[(4-bifenilmetil)sulfonil]-1-analil-D-fenil glicin, 11A, kao hidrokloridna sol, pripremljen je kroz tri koraka iz 330 mg N-a-(benziloksikarbonil)- L-y-glutamil-1-cisteinil-D-fenil glicina otapanjem amino-zaštitnog peptida u acetonitril/voda, dodavanjem približno 10-orostruki suvišak natrijeva bikarbonata, i malim dodatkom 4- (bromometil)bifenila, 1 održavanjem reakcije pod dušikom do kraja.
Antibody 006-H08 or defined maturated variants thereof according to table 5 or antigen-binding fragments thereof which antagonize prolactin receptor-mediated signaling and which bind to epitopes of the extracellular domain of the prolactin receptor and human polymorphic variants thereof, whereby the amino acid sequence of the extracellular domain of the prolactin receptor corresponds to SEQ ID NO: 70, and the nucleic acid sequence corresponds to SEQ ID NO: 71, whereby SEQ ID NO: 1 of the variable heavy chain corresponds to HCDR1, SEQ ID NO: 7 corresponds to HCDR2, SEQ ID NO: 13 corresponds to HCDR3, and SEQ ID NO: 18 of the variable light chain corresponds to LCDR 1, SEQ ID NO: 24 corresponds to LCDR2 and SEQ ID NO: 29 corresponds to LCDR3, or whereby 
Antitijelo 005-C04 ili njihove definirane sazrjele varijante u skladu s tablicom 5 ili njegov fragment koji veže antigene koji antagonizira signalizaciju posredovanu s prolaktinskim receptorom (PRLR) i koje se veže na epitope izvanstanične domene receptora prolaktina i njihove ljudske polimorfne varijante naznačeno time da sekvenca amino kiseline izvanstanične domene prolaktin receptora odgovara SEQ ID NO: 70, te sekvenca nukleinske kiseline odgovara SEQ ID NO: 71, pri čemu SEQ ID NO: 6 promjenjivog teškog lanca antitijela 005-C04 odgovara HCDR1, Seq ID NO: 12 odgovara HCDR2 i Seq ID NO: 17 odgovara HCDR3, i Seq ID NO: 23 promjenjivog lakog lanca odgovara LCDR1, Seq ID NO: 28 odgovara LCDR2 i Seq ID NO: 33 odgovara LCDR3, te pri čemu
The DNA polymerase chimera according to claim 12, wherein the modified φ29 type DNA polymerase of (a) lacks detectable exonuclease activity with respect to the corresponding naturally occurring DNA polymerase. 
DNK polimeraza himera prema zahtjevu 11, gdje se kod modificiranog tipa 029 DNK polimeraze od (a) ne detektira eksonukleazno djelovanje u odnosu n odgovarajuću prirodno pojavljivanje DNK polimeraze.
It is thus possible in practice to free the groove structures 4 completely from residues of filling medium, and to produce microfluidic arrangements with very low rejection rates. 
Tako je u praksi moguće potpuno oslobađanje brazdastih struktura 4 od ostataka punila, i mogu se proizvesti mikrofluidne naprave s vrlo niskim udjelom otpada.
filing said cavity with a dental filling material as defined above; and 
(b) punjenje rečene šupljine s dentalnim materijalom za punjenje kao što je gore definirano, te
a control head (120) adapted to determine a temperature of said primary heating liquid; 
(54) Naziv izuma: = ELEKTRIČNI SISTEM ZA ZAGRIJAVANJE, KONTROLNA GLAVA I TEKUĆINA ZA ZAGRIJAVANJE
or a pharmaceutically acceptable salt thereof, 
je farmaceutski prikladan kation;
What can thereby be prevented, for instance, is that flow seams are formed at points where such is unwanted. 
Ono što se time može spriječiti, na primjer, je da se šavovi tečenja oblikuju na mjestima gdje je takovo nešto nepoželjno.